Phase III BRUIN CLL-314 Trial is Now Enrolling Patients with CLL, SLL

By Cecilia Brown, Jennifer Woyach, MD - Last Updated: June 1, 2023

Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, speaks about the BRUIN CLL-314 study.

The phase III study will evaluate pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. It is currently enrolling patients.

Dr. Woyach and colleagues presented information about the study’s design and enrollment process during the 2023 American Society of Clinical Oncology Meeting.

Post Tags:ASCO2023
Editorial Board